Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM32 pre-seasonal dosing schedules in grass pollen allergy
2015-004551-43Phase 2Completed
- Sponsor
- Biomay AG
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of BM32 in grass pollen allergy (4 arms), sponsored by Biomay AG. Primary endpoints: Allergen-specific IgG4 level at peak grass pollen season and Allergen-specific IgG1 level at peak grass pollen season. Started Nov 2015; status: completed.
02
Drugs
BM32
03
Conditions
grass pollen allergy
Beyond the preview
Go deeper on 2015-004551-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004551-43.